{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-221756","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.926558+00:00","generated_at":"2026-05-17T05:25:33.887997+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Climb Bio reports CLYM116 preclinical data showing >70% IgA reduction and longer half-life vs sibeprenlimab","bullets":["In nonhuman primate study, CLYM116 showed ~2-3 times longer half-life and deeper IgA reduction vs sibeprenlimab at 6 mg/kg.","Subcutaneous CLYM116 demonstrated ~85% bioavailability and favorable tolerability in the NHP study.","CLYM116 Phase 1 trial in healthy volunteers expected to start Q4 2025 with initial data mid-2026.","CLYM116 is the only known 'sweeper' anti-APRIL monoclonal antibody in development for IgA nephropathy.","Updated KDIGO 2025 guideline highlights need for more active IgAN management, expanding potential market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-221756","json":"https://secwatch.observer/filing/0001193125-25-221756.json","markdown":"https://secwatch.observer/filing/0001193125-25-221756.md","text":"https://secwatch.observer/filing/0001193125-25-221756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525221756/0001193125-25-221756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525221756/d942245d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T05:25:33.887997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}